Simon Yates will not take part in the Critérium du Dauphiné in France, starting on Sunday, June 5. The British rider returned an ‘adverse analytical finding’ for asthma drug Terbutaline at Paris-Nice in March and although he was not provisionally suspended, he is unlikely to return to competition until the UCI delivers its final ruling on the case.
Cycling Weekly understands that Orica-GreenEdge, which took responsibility for the positive, attributing it to a Therapeutic Use Exemption (TUE) administrative error, won’t start the 23-year-old until then.
Yates was originally listed on a provisional team start list for the Critérium du Dauphiné but was not included on a confirmed line-up for the eight-day tour released overnight.
It is understood any suspension would commence from Yates’s last day of competition, which would therefore be backdated to April’s Vuelta al Pais Vasco if the Briton doesn’t race in the interim.
The burgeoning climber, along with brother Adam, is due to spearhead Orica-GreenEdge’s Tour de France team in July.
The Australian-registered outfit doesn’t anticipate a ruling from the UCI for another couple of weeks.